These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31641225)

  • 21. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma.
    Xie Y; Olkhov-Mitsel E; Alminawi S; Slodkowska E; Downes MR
    Pathol Res Pract; 2021 Oct; 226():153607. PubMed ID: 34509050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
    Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
    Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients.
    Nolte S; Zlobec I; Lugli A; Hohenberger W; Croner R; Merkel S; Hartmann A; Geppert CI; Rau TT
    J Pathol Clin Res; 2017 Jan; 3(1):58-70. PubMed ID: 28138402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.
    Yu S; Hornick JL; Gonzalez RS
    Virchows Arch; 2021 Sep; 479(3):481-491. PubMed ID: 33733343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
    Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
    Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
    Bayrak R; Haltas H; Yenidunya S
    Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Clinical and Prognostic Implications of Pluripotent Stem Cell Markers Expression and Their Correlation with the WNT signal pathway in Hepatocellular Carcinoma.
    Osman NAA; Khalil AI; Yousef RK
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2961-2970. PubMed ID: 33112555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
    Dabir PD; Svanholm H; Christiansen JJ
    APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation reprogramming in gastric intestinal metaplasia and dysplasia: role of SOX2 and CDX2.
    Camilo V; Garrido M; Valente P; Ricardo S; Amaral AL; Barros R; Chaves P; Carneiro F; David L; Almeida R
    Histopathology; 2015 Feb; 66(3):343-50. PubMed ID: 25196071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
    Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
    Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multispectral imaging reveals hyper active TGF-β signaling in colorectal cancer.
    Yang L; Liu Z; Tan J; Dong H; Zhang X
    Cancer Biol Ther; 2018 Feb; 19(2):105-112. PubMed ID: 29219668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.
    Olsen J; Espersen ML; Jess P; Kirkeby LT; Troelsen JT
    Surg Oncol; 2014 Sep; 23(3):167-76. PubMed ID: 25126956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant SOX2 expression in colorectal cancers does not correlate with mucinous differentiation and gastric mucin MUC5AC expression.
    Raghoebir L; Biermann K; Kempen MB; Dubbink HJ; Dinjens WN; Hersmus R; Looijenga LH; Bruno MJ; Tibboel D; Rottier RJ; Smits R
    Virchows Arch; 2014 Oct; 465(4):395-400. PubMed ID: 25108707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.
    Koopman T; de Bock GH; Buikema HJ; Smits MM; Louwen M; Hage M; Imholz ALT; van der Vegt B
    Histopathology; 2018 Jan; 72(2):191-200. PubMed ID: 28746978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms.
    Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
    Histopathology; 2019 May; 74(6):917-924. PubMed ID: 30585668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.